CD274 and neoplasm: Moreover, a study completed by Park et al. (2015), found that out of 37 tumor tissue samples, 94% had PD-L1 expression, suggesting that new therapeutic modalities could potentially target PD-L1 and its PD-1 receptor through immunotherapy [43].